Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000460284 | SCV000541853 | uncertain significance | Neuroblastoma, susceptibility to, 3 | 2023-07-21 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 404344). This variant has not been reported in the literature in individuals affected with ALK-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.0009%). This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 1078 of the ALK protein (p.Tyr1078Cys). |
| Ambry Genetics | RCV002323676 | SCV002609516 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-10-01 | criteria provided, single submitter | clinical testing | The p.Y1078C variant (also known as c.3233A>G), located in coding exon 20 of the ALK gene, results from an A to G substitution at nucleotide position 3233. The tyrosine at codon 1078 is replaced by cysteine, an amino acid with highly dissimilar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |